The United States’ Food and Drug Administration has just approved a new drug to fight HIV in combination with other antiretrovirals that are already on the market. The drug is called Edurant, and it was made by New Jersey based Tibotec Therapeutics. It works by blocking the HIV from replicating and is part of a class of drugs known as non-nucleoside reverse transcriptase inhibitor.
“Patients may respond differently to various HIV drugs or experience varied side effects,” said Edward Cox, director of the office of antimicrobial products in the FDA’s Center for Drug Evaluation and Research.
“FDA’s approval of Edurant provides an additional treatment option for patients who are starting HIV therapy.”
The FDA also approved a long awaited drug for the treatment of Hepatitis C, which was developed by Vertex Pharmaceuticals. The drug is called Incivek, and it is so effective that the chances of a person being cured of the disease double with its’ use. This drug works in combination with others such as ribavirin and pegylated interferon. It was unanimously approved by the FDA, and Vertex founder and former CEO Joshua Boger remarked that this is “a great day for patients that we at Vertex envisioned almost 18 years ago.”